NeuroPace (NPCE) Tops Q2 EPS by 4c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
August 13, 2024 4:05 PM EDT-- Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 --
-- Increased full-year 2024 revenue guidance to $76 million to $78 million --
-- Demonstrated continued operating discipline as evidenced by further decrease in cash burn --
-- Management scheduled to host a conference call today at 4:30 p.m. ET --
MOUNTAIN VIEW, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy,... More
